The 25-basis-point reduction aims to bolster a cooling economy amid slower job growth and easing inflation.
Citing a weakening labor market, the central bank lowered its benchmark rate by 25 basis points to a target range of 4.0% to 4.25%.
S&P Global Ratings report highlights risks of low profitability and credit shocks in the Chinese banking sector as Beijing prioritizes economic growth.
Phase IV trial data reveals the drug helps patients achieve LDL-C goals with reduced muscle pain, bolstering its market position.
Zilebesiran, a twice-yearly injection, will be tested in 11,000 high-risk patients following promising mid-stage results.
New analyses from the REDUCE-IT trial show a 9% reduction in hospitalizations, bolstering the drug's profile amid ongoing generic competition.
Long-term study data presented at a major cardiology conference reinforces the drug's potential in treating a rare heart condition.
Chinese proptech firm reports a 45% jump in first-half sales, but swings to a net loss as margins tighten.